Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight

The global HPV vaccines market is projected to grow from USD 8.9 billion in 2025 to USD 18.4 billion by 2034, driven by rising HPV-associated cancer prevalence, expanding government immunization programs, and advancements in multivalent vaccines. North America leads the market with 41% share, while Asia-Pacific emerges as a significant growth contributor. Key developments include Merck's presentation of long-term vaccine effectiveness data and China's approval of the first domestically-developed 9-valent HPV vaccine.

06/24/2026, 1:00 PM • GlobeNewswire

Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics announced completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class oral PKM2 modulator for moderate to severe atopic dermatitis, ahead of schedule. The trial enrolled 50 patients across US and European sites and is expected to readout in Q4 2026. The milestone follows positive Phase 1a data showing safety and immunomodulation of type 2 inflammation.

06/22/2026, 7:00 AM • GlobeNewswire

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.

06/17/2026, 1:29 PM • Benzinga

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK agreed to acquire Nuvalent for $10.6 billion in cash, marking its largest acquisition in over a decade. The deal provides GSK with three lung cancer assets including lead drug candidates zidesamtinib and neladalkib for non-small cell lung cancer treatment. The acquisition is expected to contribute to revenue growth and be accretive to sales and core operating profit beginning in 2027.

06/09/2026, 6:52 AM • Benzinga

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Eli Lilly announced three infectious disease acquisitions in a single day—Curevo (shingles vaccine), LimmaTech Biologics (bacterial pathogen vaccines), and Vaccine Company (viral infection prevention)—totaling over $3.8 billion. These deals signal management's strategy to diversify beyond its blockbuster obesity drugs (Zepbound and Mounjaro) and build new growth engines focused on disease prevention, particularly addressing antimicrobial resistance and infections linked to serious conditions like multiple sclerosis and cancer.

06/08/2026, 5:23 PM • The Motley Fool

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

Sitryx to Participate in Upcoming Investor Conferences

Sitryx Therapeutics, a clinical-stage biopharmaceutical company, announced participation in three major investor conferences (Jefferies Global Healthcare, J.P. Morgan European Healthcare Forum, and Evercore Emerging Private Biotech) in June 2026. The company is developing novel oral therapies for autoimmune and inflammatory diseases, with lead candidate SYX-5219 (PKM2 modulator) showing safety and efficacy in Phase 1a trials, and a GLS1 inhibitor nominated for clinical development in asthma.

05/18/2026, 7:00 AM • GlobeNewswire

First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, a first-in-class oral pyruvate kinase M2 (PKM2) modulator for atopic dermatitis. The drug demonstrated safety, tolerability, target engagement, and evidence of systemic immunomodulation with reduced CCL17/TARC biomarker levels. A Phase 1b trial in adults with moderate to severe atopic dermatitis is underway with data expected by year-end 2026.

05/13/2026, 7:00 AM • GlobeNewswire

GSK Targets China's Hepatitis B Market Through New Deal

GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.

05/11/2026, 12:03 PM • Benzinga

Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor Intelligence

The antibiotic resistance market is projected to grow from USD 9.78 billion in 2026 to USD 12.72 billion by 2031 at a 5.4% CAGR, driven by rising multidrug-resistant infections and innovations in rapid diagnostics and novel antimicrobials. North America leads the market while Asia-Pacific emerges as a high-growth region.

04/28/2026, 3:52 AM • GlobeNewswire